HUP0300419A2 - Ösztrogén agonista/antagonista metabolitok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Ösztrogén agonista/antagonista metabolitok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0300419A2 HUP0300419A2 HU0300419A HUP0300419A HUP0300419A2 HU P0300419 A2 HUP0300419 A2 HU P0300419A2 HU 0300419 A HU0300419 A HU 0300419A HU P0300419 A HUP0300419 A HU P0300419A HU P0300419 A2 HUP0300419 A2 HU P0300419A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- general formula
- pyrrolidin
- formula
- pharmaceutical compositions
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 239000002207 metabolite Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940097043 glucuronic acid Drugs 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- -1 2-oxo-pyrrolidin-1-yl group Chemical group 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Abstract
A jelen találmány tárgyát olyan vegyületek képezik, amelyek a (-)-cisz-6-fenil-5-[4-(2-(pirrolidin-l-il-etoxi)-fenil]-5,6,7,8-tetrahidro- naftalin-2-ol (I) általános képletű metabolitjai. Atalálmány szerinti vegyületek analitikai vizsgálatokhoz standardkénthasználhatók; valamint kémiai anyagok további kémiai szintézise vagybioszintézise során intermedierként szolgálhatnak. A találmány továbbitárgyát betegségek kezelésére szolgáló gyógyszerészeti készítmények éseljárások képezik. Az (I) általános képletben az R1 jelentésepirrolidin-l-il- vagy 2-oxo-pirrolidin-l-il -csoport, az (a) általánosképletű csoport vagy az -NH(CH2)3C-OR6 általános képletű csoport; azR5 jelentése hidrogénatom, metilcsoport, glükuronsav, vagyszulfocsoport; az R2, az R3, az R4 és az R7 jelentése azonos vagykülönböző, és ezek a következők közül kerülhetnek ki: hidrogénatomvagy az OR5 általános képletű csoport; továbbá az R6 jelentésehidroxi-csoport, az -NHCH2COOH vagy az -NHCH2CH2SO3H képletű csoport,illetve glükuronsav. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26719800P | 2000-04-07 | 2000-04-07 | |
PCT/IB2001/000427 WO2001077093A1 (en) | 2000-04-07 | 2001-03-19 | Estrogen agonist/antagonist metabolites |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300419A2 true HUP0300419A2 (hu) | 2003-06-28 |
HUP0300419A3 HUP0300419A3 (en) | 2005-07-28 |
Family
ID=23017734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300419A HUP0300419A3 (en) | 2000-04-07 | 2001-03-19 | Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use |
Country Status (38)
Country | Link |
---|---|
US (2) | US6455572B1 (hu) |
EP (1) | EP1268453B1 (hu) |
JP (1) | JP2004510693A (hu) |
KR (1) | KR20020089434A (hu) |
CN (1) | CN1209353C (hu) |
AP (1) | AP2002002641A0 (hu) |
AR (1) | AR035330A1 (hu) |
AT (1) | ATE333450T1 (hu) |
AU (2) | AU2001240985B2 (hu) |
BG (1) | BG107137A (hu) |
BR (1) | BR0109838A (hu) |
CA (1) | CA2405070A1 (hu) |
CR (1) | CR6766A (hu) |
CZ (1) | CZ20023223A3 (hu) |
DE (1) | DE60121557T2 (hu) |
DK (1) | DK1268453T3 (hu) |
EA (1) | EA004866B1 (hu) |
EE (1) | EE200200580A (hu) |
ES (1) | ES2266169T3 (hu) |
HK (1) | HK1052511B (hu) |
HR (1) | HRP20020802A2 (hu) |
HU (1) | HUP0300419A3 (hu) |
IL (1) | IL152082A0 (hu) |
IS (1) | IS6549A (hu) |
MA (1) | MA26890A1 (hu) |
MX (1) | MXPA02009940A (hu) |
NO (1) | NO20024767L (hu) |
OA (1) | OA12325A (hu) |
PA (1) | PA8514901A1 (hu) |
PE (1) | PE20011183A1 (hu) |
PL (1) | PL358593A1 (hu) |
PT (1) | PT1268453E (hu) |
SK (1) | SK14092002A3 (hu) |
TN (1) | TNSN01052A1 (hu) |
TR (1) | TR200202310T2 (hu) |
UY (1) | UY26656A1 (hu) |
WO (1) | WO2001077093A1 (hu) |
ZA (1) | ZA200207995B (hu) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US7001926B2 (en) | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
CZ20002567A3 (cs) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
US7479504B2 (en) * | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
AU2003208516A1 (en) * | 2002-03-14 | 2003-09-22 | Warner-Lambert Company Llc | Method for characterizing metabolites using hydrogen/deuterium exchange |
US20050095241A1 (en) * | 2003-08-26 | 2005-05-05 | Vadlamudi Ratna K. | Estrogen receptor modulators and uses thereof |
US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
AU2012200714B2 (en) * | 2004-08-13 | 2014-04-17 | Wyeth Llc | Tanaproget derivatives, metabolites, and uses thereof |
PT1778710E (pt) * | 2004-08-13 | 2012-04-12 | Wyeth Llc | Derivados de tanaproget, metabolitos e suas utilizações |
WO2006136944A1 (en) * | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride |
US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
-
2001
- 2001-03-19 DK DK01912069T patent/DK1268453T3/da active
- 2001-03-19 AU AU2001240985A patent/AU2001240985B2/en not_active Ceased
- 2001-03-19 KR KR1020027013379A patent/KR20020089434A/ko active Search and Examination
- 2001-03-19 CA CA002405070A patent/CA2405070A1/en not_active Abandoned
- 2001-03-19 PL PL01358593A patent/PL358593A1/xx not_active Application Discontinuation
- 2001-03-19 EE EEP200200580A patent/EE200200580A/xx unknown
- 2001-03-19 AT AT01912069T patent/ATE333450T1/de not_active IP Right Cessation
- 2001-03-19 BR BR0109838-1A patent/BR0109838A/pt not_active IP Right Cessation
- 2001-03-19 SK SK1409-2002A patent/SK14092002A3/sk unknown
- 2001-03-19 WO PCT/IB2001/000427 patent/WO2001077093A1/en active IP Right Grant
- 2001-03-19 AU AU4098501A patent/AU4098501A/xx active Pending
- 2001-03-19 CZ CZ20023223A patent/CZ20023223A3/cs unknown
- 2001-03-19 HU HU0300419A patent/HUP0300419A3/hu unknown
- 2001-03-19 JP JP2001575567A patent/JP2004510693A/ja not_active Withdrawn
- 2001-03-19 PT PT01912069T patent/PT1268453E/pt unknown
- 2001-03-19 CN CNB018077935A patent/CN1209353C/zh not_active Expired - Fee Related
- 2001-03-19 EA EA200200949A patent/EA004866B1/ru not_active IP Right Cessation
- 2001-03-19 EP EP01912069A patent/EP1268453B1/en not_active Expired - Lifetime
- 2001-03-19 MX MXPA02009940A patent/MXPA02009940A/es active IP Right Grant
- 2001-03-19 AP APAP/P/2002/002641A patent/AP2002002641A0/en unknown
- 2001-03-19 TR TR2002/02310T patent/TR200202310T2/xx unknown
- 2001-03-19 OA OA1200200305A patent/OA12325A/en unknown
- 2001-03-19 ES ES01912069T patent/ES2266169T3/es not_active Expired - Lifetime
- 2001-03-19 DE DE60121557T patent/DE60121557T2/de not_active Expired - Fee Related
- 2001-03-19 IL IL15208201A patent/IL152082A0/xx unknown
- 2001-04-04 US US09/825,980 patent/US6455572B1/en not_active Ceased
- 2001-04-05 PE PE2001000320A patent/PE20011183A1/es not_active Application Discontinuation
- 2001-04-05 UY UY26656A patent/UY26656A1/es not_active Application Discontinuation
- 2001-04-05 AR ARP010101626A patent/AR035330A1/es unknown
- 2001-04-06 TN TNTNSN01052A patent/TNSN01052A1/fr unknown
- 2001-04-09 PA PA20018514901A patent/PA8514901A1/es unknown
-
2002
- 2002-09-17 IS IS6549A patent/IS6549A/is unknown
- 2002-09-23 BG BG107137A patent/BG107137A/bg unknown
- 2002-10-02 MA MA26847A patent/MA26890A1/fr unknown
- 2002-10-02 CR CR6766A patent/CR6766A/es not_active Application Discontinuation
- 2002-10-03 NO NO20024767A patent/NO20024767L/no not_active Application Discontinuation
- 2002-10-04 ZA ZA200207995A patent/ZA200207995B/en unknown
- 2002-10-07 HR HR20020802A patent/HRP20020802A2/hr not_active Application Discontinuation
-
2003
- 2003-05-30 US US10/448,751 patent/USRE39419E1/en not_active Expired - Fee Related
- 2003-07-08 HK HK03104866.0A patent/HK1052511B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300419A2 (hu) | Ösztrogén agonista/antagonista metabolitok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303084A2 (hu) | Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
JP7450559B2 (ja) | 疾患の処置のためのkdm1a阻害剤 | |
HUP0302581A2 (hu) | Karboxamidok mint mezőgazdasági fungicidek, előállításuk és alkalmazásuk | |
HUP0300434A2 (hu) | Oxazolszármazékok és alkalmazásuk tirozin-kináz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0202814A2 (hu) | Androgénreceptor moduláló vegyületek és eljárás azok előállítására és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0402507A2 (hu) | N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények | |
MXPA05006907A (es) | Compuestos diazoicos cationicos, composiciones que los contienen como colorante directo, procedimiento de coloracion de fibras queratinicas y dispositivo. | |
HUP0103987A2 (en) | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates | |
MXPA05006909A (es) | Compuestos diazoicos cationicos particulares, composiciones que los contienen como colorante directo, procedimiento de coloracion de fibras queratinicas y dispositivo. | |
HUP0203836A2 (hu) | 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
PT1263725E (pt) | Novos compostos | |
SE0103836D0 (sv) | Novel compounds | |
DK1077927T3 (da) | Nye substituerede cykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse | |
MXPA02012033A (es) | Derivados de 2-aminocarbonil-9h-purina. | |
NO20060314L (no) | Nicotinamid-derivater anvendbare som PDE4-inhibitorer | |
ATE303366T1 (de) | 4-amino-5-cyano-2-anilino-pyrimidin-derivate zur verwendung als inhibitoren von zellzyklus-kinasen | |
MXPA05012247A (es) | Derivados de bencimidazol nuevos. | |
HUP0401886A2 (hu) | Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
ME00428B (me) | 5-hlor0-3-(4-metansulfonilfenil)-6'-metil-(2,3')bipiridinil u čistom kristalnom obliku i postupak sinteza | |
SE0403171D0 (sv) | New compounds | |
TW200512201A (en) | New heterocyclic amides | |
ATE498600T1 (de) | Inden derivate als pharmazeutika | |
HUP0204394A2 (en) | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | |
HUP0202433A2 (hu) | NMDA receptor antagonista hatású helyettesített pirrolidin-2,3,4-trion-3-oxim-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |